Wellington Management Group LLP Rotates from Big Tech Winners to Durable Cash Engines

The single loudest statement is the new AstraZeneca position at 0.86% of the book. Dropping roughly $4.63B into a large-cap pharma with oncology and immunology depth says they want more defensible earnings and pipeline-driven growth, not just GLP‑1 beta.

Around that, they are methodically reinforcing the “infrastructure” behind secular themes rather than doubling down on the flashiest front-ends:

• Microsoft is up 7.8%, Broadcom 4.9%, and Taiwan Semi 39.8%, while KLA explodes 228.9% higher. This is a pivot from pure AI poster child exposure toward the compute stack and semicap tools that monetize AI demand over a full cycle.
• Meta is up 33.2% and Netflix 68.2%, a clear bet that scaled ad/video platforms still have operating leverage and pricing power even after big runs.
• In health care, they quietly add to Eli Lilly, Stryker, Abbott, and Philip Morris (reclassified here via medicinal products), building a diversified, cash-rich complex around the new AstraZeneca stake.
• Financial tollbooths get a major vote of confidence: BlackRock is up 151.2%, S&P Global 26.8%, Marsh & McLennan 8.6%, and AIG 9.5%. That’s a curated basket of fee streams on assets, data, risk, and credit that compound irrespective of which specific style factor is in vogue.
• On the macro front, they turbocharge Diamondback Energy by 285.9% and add 23.2% to TotalEnergies, while also lifting Exxon. This is a conscious choice to own upstream and integrated producers as a hedge against inflation and supply constraints.
• Defense and industrial resilience are another emerging theme: Northrop Grumman is up 77.5% and Honeywell 29.9%, while they still carry Tesla but no longer treat it as sacrosanct growth.

Taken together, the “buy” list says Wellington wants operating leverage to AI, rearmament, energy scarcity, and financialization – but prefers businesses that collect fees, royalties, and rents over pure volume growth.

On the sell side, Wellington is not capitulating on losers; they are harvesting winners and pruning cyclicals. Apple is cut by 15.9%, Alphabet’s GOOGL line by 16.9%, and Nvidia by 4.9%, all from deeply profitable bases (each well over 100%+ gain vs average cost). These look like risk-budget decisions: the AI and big-tech thesis is intact, but position sizes were simply too fat.

The health-care trims are more nuanced. UnitedHealth is slashed by 35.7% and Johnson & Johnson by 13.6%, even as they add aggressively elsewhere in the sector. That smells like a rotation within health care from managed care and diversified pharma into higher-growth or more pipeline-levered names like AstraZeneca, Lilly, Stryker, and Abbott.

Consumer and rate-sensitive names are a clear funding source:

• Amazon is down 5.8%, Home Depot 10.1%, TJX 24.2%, and PCAR 19.5%. They’re dialing back exposure to discretionary and housing-related demand just as macro softness bites and the easy post-COVID comps are behind us.
• Real estate-linked exposures like Welltower and Mastercard (classified here as Real Estate in the feed) are trimmed modestly, while Visa is increased – a tilt toward higher-margin payments rails vs interest-rate sensitive property.
• In utilities and pipelines, they shave 18.6% off Targa, 1.1% off Sempra, and nudge Dominion higher, a subtle shift from midstream beta into more regulated, rate‑base style utilities.

The through-line: they’re less interested in “good businesses at any price” and more focused on where the next dollar of risk earns a truly differentiated return.

Despite the trims, technology is still the dominant exposure at 41.99%; this is not a style drift away from growth. But that share is down from 43.97%, and inside tech there is a rotation from the most crowded mega-caps (Apple, Alphabet, Nvidia, Texas Instruments) toward infrastructure and enablers like Microsoft, Broadcom, TSMC, NXP, and KLA.

Health care is the clear winner of the rebalancing. Sector weight rises from 16.62% to 17.48% on the back of the new AstraZeneca stake and adds to Lilly, Abbott, Stryker, and Philip Morris, even as they shrink UnitedHealth and J&J. They’re turning health care into a second core engine of the book alongside tech.

Energy jumps from 2.33% to 3.22%, a big move at the margin. The outsized additions to Diamondback and TotalEnergies, plus more Exxon, reposition the sleeve toward producers that benefit from any sustained tightness in oil and gas markets, while utilities slip from 4.73% to 4.31% as Targa and Sempra get trimmed.

Financials and industrials are also quietly on the rise: finance moves from 7.83% to 8.4%, industrials from 4.55% to 5.14%. That’s the cumulative impact of doubling down on BlackRock, S&P Global, Marsh & McLennan, AIG, Northrop, and Honeywell – a broad bet on fee, data, and defense resilience over pure rate-beta banks.

Taken as a whole, this 13F says Wellington is preparing for a world where AI, health innovation, and deglobalization continue – but market leadership broadens beyond the handful of mega-cap darlings that dominated the last three years. The firm is deliberately trading some upside in the most crowded tech winners for sturdier, cash-flowing exposure across pharma, semis infrastructure, energy producers, and financial tollbooths.

They are also using a rough quarter to upgrade quality inside cyclical sleeves. Retail, housing-linked, and some managed care exposure are being recycled into names with better pricing power, regulatory moats, or structural demand – Netflix and Disney in content, BlackRock and S&P Global in financial plumbing, Northrop in defense, Diamondback in low-cost shale.

Going forward, expect Wellington to keep technology and health care as twin pillars, but with more emphasis on “picks and shovels” and pipelines than on the headline narratives. Energy and defense now serve as macro hedges that can work even if multiples compress elsewhere. The portfolio suggests they’re positioning not for a crash, but for a grind: mid- to high-single-digit revenue growth, modest multiple deflation, and outsized rewards for businesses that can grow cash flows in that environment.

If the market broadens beyond the same five mega-caps, this book is built to participate. If it doesn’t, they’ve at least taken some money off the table in the names that would hurt most on the way down.